Sarah Cohen, an 11-year-old who lives in Geelong, near Melbourne, started taking vosoritide at age 7. Photo / Christina Simons, The New York Times
An experimental medication that increases height in children with the most common form of dwarfism has raised hope that it can help them lead easier lives. But some say the condition is not a problem in need of a cure.
It's a question many parents of children with dwarfism have contemplated: If a medication could make them taller, would they give it to them?
Now, that possibility is becoming less hypothetical. A study published this weekend in the journal The Lancet found that an experimental drug called vosoritide increased growth in children with the most common form of dwarfism to nearly the same rate as in children without the condition.
The study has raised hope that the drug, if taken over the course of years, can make life easier for those with the condition, known as achondroplasia, including the distant prospect of alleviating major quality-of-life issues such as back pain and breathing difficulties.
But the drug has also ignited a contentious debate in a community that sees "dwarf pride" as a hard-won tenet — where being a little person is a unique trait to be celebrated, not a problem in need of a cure.
Weeks before their son Lachlan was born, Dr. Simone Watkins and her husband learned that he most likely had achondroplasia, which affects about 1 in 25,000 infants.
After his birth, Watkins recalled, she and her husband said over him: "We love you. You're perfect. We are so happy you're here. You're going to have a great life."
She now feels that vosoritide could compromise that sentiment.
"I want him to have the best life possible with less complications and not to be bullied and to fit into society," Watkins said as Lachlan, 2, played next to her in a pile of pillows at their home in Auckland. "But also, I don't want to give him the message that he needs to change."
Achondroplasia is a genetic disorder that disrupts the transition of cartilage to bone. Those with the condition have shorter arms and legs than those found in people of average stature, as well as defining facial features. Their adult height is typically a little over 4 feet (1.2 metres). More than 80 per cent of those with achondroplasia are born to parents of average stature, and a child with the condition has a 50 per cent chance of passing it on.
The study in The Lancet found that children who took the drug grew an additional 0.6 inches on average in one year, with minimal side effects. If taken over many years, vosoritide could produce a significant increase in adult height, although the study was limited to a year and does not address this possibility, or resolve whether the medication can ease the medical complications common to dwarfism.
The trial examined 121 children ages 5 to 17 over a 12-month period. Participants were located in seven countries.
In August, BioMarin, the American pharmaceutical company behind vosoritide, submitted the study's findings to the Food and Drug Administration as well as the European Medicines Agency. If approved, vosoritide could be available within months.
"It doesn't totally restore all of the growth, but it does make a pretty significant dent in the difference," said Dr. Eric Rush, a clinical geneticist at Children's Mercy Hospital in Kansas City, Missouri, and an associate professor of paediatrics at the University of Missouri, Kansas City.
He was not involved in the vosoritide trial but has consulted for BioMarin and is involved in trials for a similar drug.
Vosoritide utilises a synthetic form of a protein that humans produce naturally. It targets the overactive signal that prevents bone growth in children with achondroplasia, said Dr. Ravi Savarirayan, a clinical geneticist at the Murdoch Children's Research Institute in Melbourne, Australia, who led the trial.
He compared the condition's effects to watering a plant. "It's not going to grow if it gets too much water, so we are just regulating the amount of water," Savarirayan said, calling the drug a "precision therapy that actually counteracts the underlying problem."
Savarirayan offered a moving example of what longer limbs could deliver.
"We've got 12- and 13-year-old girls who now for the first time can do their own feminine hygiene and don't need to be helped by someone because their arms are longer," he said.
Sarah Cohen, an 11-year-old who lives in Geelong, near Melbourne, started taking vosoritide at age 7 and continues to use it as part of another trial.
At 4 feet, 1 inch (1.24 metres) tall, she has already reached what her full adult height could have been without vosoritide. In the early stages of her treatment, she dreaded the daily injections. "I got used to it," she said, "and I am growing."
That has produced some milestones that others might take for granted. When her family returned to a water park recently, she cleared the 4-foot height requirement to use a waterslide for the first time. "There's a real confidence that goes with those things," said her father, Paul Cohen.
Megan Schimmel attributes much of her strength, compassion and empathy to living with achondroplasia. She said that she wouldn't want to change herself and that she isn't going to change her 2-year-old daughter, Lily, who also has the condition.
"I can do everything that someone a foot taller can do, with minor accommodations," Schimmel wrote in an email, adding that vosoritide sent a message that those with achondroplasia "are broken."
Melissa Mills, of Jacksonville, Florida, who does not have the condition, said she had already decided that her 4-year-old daughter, Eden, would use vosoritide if it is approved by the FDA.
Yes, Mills could get a $900 custom bike so her daughter could ride or teach her to drive a car with pedal extenders, but she will embrace an alternative. "With dwarfism, the world wasn't built for my child, so if there is something I can do to help her navigate the world a little bit better and on her own, I want to do it," she said.
After Eden's diagnosis, Mills said, she joined every support group she could find to learn about her daughter's condition. Her questions about treatments that increased height whipped up tension. "The more I got involved in the groups and the LPA" — the organisation Little People of America — "the more I pulled away."
The debate over the drug resembles a decadeslong discussion among deaf people over cochlear implants, with some taking exception to the suggestion that they should be "fixed" with the device.
Vosoritide, said Mark Povinelli, LPA's president, "is one of the most divisive things that we've come across in our 63-year existence."
The organisation does not endorse specific treatments but encourages members to consider more than height in medical decisions. "We want to show that you can have a completely fulfilling life without having to worry about growth velocity," said Povinelli, calling fixations on height a societal issue.
When the group formed in 1957, there were no treatments in the United States to increase height. The organisation focused on changing how the outside world saw people with the condition, emphasising pride and forming a community that now numbers 8,000.
In 2012, when BioMarin first presented vosoritide to the group, it received a lackluster response, Povinelli said. An uneasy truce has since developed.
"For better or for worse, as uncomfortable as it was, it put these therapies front and center in everyone's mind," he said.
The drug — whose price has not yet been set, although it is likely to be costly — could provide an alternative to arduous limb-lengthening surgery, a process that involves cutting bone and extending a limb over several weeks, said Marco Sessa, the president of the Association for the Information and Study of Achondroplasia in Italy.
The surgery has not caught on in the United States as it has in Italy, where more than 90 per cent of people with achondroplasia undergo it, adding a foot of height in some cases. "It is a very painful, long operation, so people think with the vosoritide we will finish the era of leg-lengthening," Sessa said.
Watkins, the paediatric trainee in Auckland, said that she and her husband were leaning toward treating their son with vosoritide. It isn't so much about the height, she said, but the potential quality-of-life benefits.
Still, Watkins wonders about the effects on Lachlan's relationships with his peers who have dwarfism if he grows taller than they do. She also worries about the potential for negative side effects that did not show up in the trials.
For now, she will wait, if vosoritide is approved, to see how it continues to perform. "I don't think it is very straightforward," she said.
Written by: Serena Solomon
Photographs by: Christina Simons
© 2020 THE NEW YORK TIMES
More than 60 fighter jets hit alleged missile production sites in Tehran.